Co-occurring substance use disorder in schizophrenia

The combination of schizophrenia and substance use disorder is so common that clinicians have a name for it — "dual diagnosis," or in newer language, "co-occurring disorders." Different studies put the lifetime prevalence of any substance use disorder in people with schizophrenia at around 47%, compared with 16% in the general population. That overlap shapes outcomes more than almost any other variable: it predicts more relapses, more hospitalisations, worse housing stability, higher cardiovascular and infectious disease risk, and higher mortality.

How common is it, by substance?

Drawing on the Epidemiologic Catchment Area study and subsequent surveys, lifetime prevalence in schizophrenia is approximately:

• Tobacco use disorder — around 60% (covered in our smoking cessation article)
• Alcohol use disorder — around 30%
• Cannabis use disorder — around 25%
• Other illicit drug use disorder — around 10–15%

Why the overlap is so high

Self-medication

Many people describe substance use as helping with specific symptoms — alcohol or cannabis to quiet voices or anxiety, stimulants to push through negative symptoms, opioids to dull pain or distress. This rarely works long-term, but the short-term reinforcement is real.

Shared biology

Schizophrenia and addiction share dopaminergic pathways and reward-system dysregulation. Some genetic risk variants overlap. The brains that develop psychosis appear to be more vulnerable to substance dependence, even at lower doses.

Social context

Marginalisation, unstable housing, poverty, and trauma all increase substance use risk — and all are common in serious mental illness.

Cannabis and psychosis specifically

The relationship between cannabis and psychosis deserves separate mention. Heavy adolescent cannabis use, particularly of high-THC products, is associated with a substantially increased risk of developing psychosis — and continued cannabis use after a first episode is one of the strongest predictors of relapse. See our cannabis article.

Why outcomes are worse

• Reduced medication adherence
• More frequent relapses and hospitalisations
• Higher rates of homelessness and incarceration
• Higher rates of HIV and hepatitis C in people who inject drugs
• Greater violence risk (driven mostly by intoxication, not the psychosis itself)
• Substantially higher mortality

Why treatment has historically failed

For decades, mental health services and addiction services were funded, organised, and trained separately. People with both conditions were bounced between systems: addiction services often refused to treat people who weren't yet "psychiatrically stable," while mental health services often refused to treat people who weren't yet "clean." Patients fell into the gap.

The integrated treatment approach

The evidence is consistent: integrated treatment — same team, same building, simultaneous treatment of both conditions — outperforms parallel or sequential treatment. The Substance Abuse and Mental Health Services Administration (SAMHSA) has published detailed implementation guidance on integrated dual disorders treatment (IDDT), and it remains the gold standard model.

Core principles:

• One team treats both conditions
• Stage-matched intervention (engagement → persuasion → active treatment → relapse prevention)
• Motivational interviewing rather than confrontation
• Long-term perspective — engagement and progress are measured in years, not weeks
• Use of medications for both psychosis and addiction (e.g., clozapine, naltrexone, buprenorphine)
• Wraparound services: housing, employment, family work

Medication considerations

Antipsychotics

Clozapine has the strongest evidence among antipsychotics for reducing substance use in dual-diagnosis populations. Long-acting injectables often help people whose substance use disrupts oral medication adherence.

Addiction medications

• Alcohol use disorder: naltrexone and acamprosate are first-line; disulfiram in selected cases
• Opioid use disorder: methadone or buprenorphine, with strong evidence for mortality reduction
• Tobacco use disorder: varenicline, bupropion, and nicotine replacement — all effective and safe in schizophrenia (see smoking cessation article)
• Cannabis use disorder: no licensed medications; behavioural treatments are mainstay
• Stimulant use disorder: no licensed medications; contingency management has the best evidence

Psychosocial approaches

• Motivational interviewing: collaborative, non-confrontational
• CBT for substance use: identifies triggers and builds coping skills
• Contingency management: structured rewards for negative tests, with strong evidence
• Mutual support groups: 12-step or alternatives like SMART Recovery, with awareness that some people with psychosis find traditional 12-step environments difficult
• Housing first: stable housing without prerequisite sobriety dramatically improves outcomes

Practical first steps

1. Be honest with the clinician about substance use — concealment is one of the biggest obstacles to good care
2. Ask whether your area has an integrated dual-diagnosis program
3. If not, push for coordinated care between mental health and addiction providers
4. Discuss medication options for the specific substance involved
5. Consider whether a long-acting injectable antipsychotic would help with adherence
6. Connect with peer-support communities that understand both worlds

For specific substances, see also alcohol and schizophrenia and cannabis and psychosis.

This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.